E
Eveline P. Mauser-Bunschoten
Researcher at Utrecht University
Publications - 60
Citations - 3296
Eveline P. Mauser-Bunschoten is an academic researcher from Utrecht University. The author has contributed to research in topics: Von Willebrand disease & Population. The author has an hindex of 27, co-authored 60 publications receiving 2846 citations. Previous affiliations of Eveline P. Mauser-Bunschoten include University Medical Center Utrecht.
Papers
More filters
Journal ArticleDOI
The Nijmegen Modification of the Bethesda Assay for Factor VIII : C Inhibitors: Improved Specificity and Reliability
Bert Verbruggen,Irena Novakova,Hans J. C. T. Wessels,Jan B.M. Boezeman,Marijke van den Berg,Eveline P. Mauser-Bunschoten +5 more
TL;DR: Two modifications are proposed and tested to resolve the imperfections of the Bethesda assay and allow better discrimination between positive and negative samples and improve reliability.
Journal ArticleDOI
Bleeding in carriers of hemophilia
Iris Plug,Eveline P. Mauser-Bunschoten,Annette H. J. T. Bröcker-Vriends,Hans Kristian Ploos van Amstel,Johanna G. van der Bom,Joanna E. M. van Diemen-Homan,José Willemse,Frits R. Rosendaal +7 more
TL;DR: Findings suggest that not only clotting factor levels at the extreme of the distribution, resembling mild hemophilia, but also mildly reduced clotting factors between 0.41 and 0.60 IU/mL are associated with bleeding.
Journal ArticleDOI
The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia.
Krista Fischer,Johanna G. van der Bom,Eveline P. Mauser-Bunschoten,Goris Roosendaal,Robert Prejs,Piet de Kleijn,Diederick E. Grobbee,Marijke van den Berg +7 more
TL;DR: The effect of postponing prophylaxis on long-term arthropathy was studied in a cohort of 76 patients with severe hemophilia born between 1965 and 1985, finding that most patients have their first joint bleed after the age of 2 years.
Journal ArticleDOI
Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial.
Peter William Collins,Guy Young,Karin Knobe,Faraizah Abdul Karim,Pantep Angchaisuksiri,Claus Banner,Türkiz Gürsel,Johnny Mahlangu,Tadashi Matsushita,Eveline P. Mauser-Bunschoten,Johannes Oldenburg,Christopher E. Walsh,Claude Negrier +12 more
TL;DR: Nonacog beta pegol was well tolerated and efficacious for the treatment of bleeding episodes and was associated with low ABRs in patients receiving prophylaxis, and improved health-related quality of life with EuroQoL-5 Dimensions visual analog scale score.
Journal ArticleDOI
Age at first treatment and immune tolerance to factor VIII in severe hemophilia
TL;DR: It is confirmed that age of first factor VIII administration in children with severe hemophilia A is inversely associated with the risk to develop antibodies against factor VIII.